Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUDAFED 12 HOUR vs AFRINOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pseudoephedrine is a sympathomimetic amine that acts as an agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of nasal mucosa and reducing nasal congestion.
Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.
Temporary relief of nasal congestion due to common cold, hay fever, or other upper respiratory allergies
Temporary relief of nasal congestion due to colds, hay fever, or other upper respiratory allergies.
120 mg orally every 12 hours, extended-release tablets. Maximum 240 mg per day.
Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.
8-10 hours in adults with normal renal function; prolonged to 19-24 hours in renal impairment (Cr Cl <30 m L/min); shorter in children (3-4 hours)
9–11 hours in healthy adults; prolonged to 16–18 hours in hepatic cirrhosis and up to 20 hours in severe renal impairment. Clinical context: dosing interval typically 12 hours in normal renal function.
Hepatic metabolism via N-demethylation to active metabolite; primarily excreted unchanged in urine
Primarily hepatic metabolism via oxidative deamination and glucuronidation; the major enzyme involved is monoamine oxidase (MAO).
Renal: 74-95% as unchanged drug; 1-4% as active metabolite (norpsuedoephedrine); biliary/fecal: minimal (<1%)
Renal (approximately 70–90% as unchanged drug and metabolites), with about 10% biliary/fecal elimination. Dose adjustment required in renal impairment (Cr Cl <30 m L/min).
50-60% bound (primarily to albumin and alpha-1-acid glycoprotein)
80–90% bound to serum albumin and alpha-1-acid glycoprotein.
2.6-3.5 L/kg in adults; indicates extensive tissue distribution (higher than total body water)
4.0–5.0 L/kg. Indicates extensive tissue distribution, with concentrations exceeding plasma levels in lung, liver, kidney, and brain.
Oral: 90-100% (immediate-release); sustained-release: approximately 95%
Oral: 40–50% (first-pass metabolism). Intranasal: 70–80% (systemic absorption variable). Intravenous: 100%.
GFR 30-50 m L/min: reduce dose to 60 mg every 12 hours. GFR <30 m L/min: use is contraindicated.
Cr Cl 30-50 m L/min: prolong interval to every 18-24 hours; Cr Cl <30 m L/min: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B or C: consider reducing dose or extending interval due to reduced clearance; specific guidelines not established.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, consider dose reduction; Child-Pugh C: avoid use.
Children 6-12 years: 60 mg orally every 12 hours; maximum 120 mg/day. Children <6 years: not recommended.
Children 6-12 years: 1/2 tablet (pseudoephedrine 60 mg, triprolidine 1.25 mg) every 12 hours; maximum 1 tablet per day. Children <6 years: not recommended.
Start at lower end of dosing range (60 mg every 12 hours); monitor for CNS stimulation, hypertension, and urinary retention.
Start with 1/2 tablet (pseudoephedrine 60 mg, triprolidine 1.25 mg) every 12 hours; monitor for CNS effects, anticholinergic side effects, and hypertension.
None
None.
Cardiovascular effects: hypertension, palpitations, tachycardia,CNS stimulation: insomnia, nervousness, dizziness,Exacerbation of narrow-angle glaucoma,Exacerbation of prostatic hypertrophy/urinary retention,Diabetes mellitus: may increase blood glucose
Hypertension, cardiovascular disease, hyperthyroidism, diabetes mellitus, increased intraocular pressure, prostatic hyperplasia; use caution in elderly patients; do not exceed recommended dosage.
Severe hypertension,Coronary artery disease,Concurrent or recent (within 14 days) MAOI therapy,Narrow-angle glaucoma,Urinary retention
Hypersensitivity to any component; concurrent use or recent use (within 14 days) of MAO inhibitors; severe hypertension or coronary artery disease.
Avoid caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase central nervous system stimulation and exacerbate side effects like nervousness and insomnia. High-tyramine foods (aged cheeses, cured meats, fermented products) should be limited in patients taking MAOIs, but no direct interaction with pseudoephedrine alone. Alcohol may increase dizziness and should be avoided.
Avoid excessive caffeine intake as it may increase stimulant effects. No significant food interactions known.
Category C. First trimester: Possible risk of gastroschisis (limited data). Second and third trimesters: Uterine vasoconstriction, reduced placental perfusion; avoid due to risk of fetal hypoxia, tachycardia, and intrauterine growth restriction. No adequate well-controlled human studies.
Afrinol (pseudoephedrine) is generally considered low risk during pregnancy. First trimester: Some studies suggest a possible association with gastroschisis, but data are inconsistent. Second and third trimesters: Avoid due to risk of uterine vasoconstriction and potential fetal hypoxia, especially near term. Overall, FDA Pregnancy Category C.
Pseudoephedrine is excreted into breast milk (M/P ratio approximately 2.0-3.5). Use with caution: may reduce milk production and cause irritability in infants. Highest risk in preterm infants or those with impaired renal function. Avoid if possible; use lowest effective dose if necessary.
Pseudoephedrine is excreted into breast milk in small amounts (M/P ratio approximately 2.6–3.5). Use with caution as it can reduce milk production and may cause irritability in the infant. A single dose is likely safe, but chronic use is not recommended.
No specific dose adjustment recommended, but use is generally avoided in pregnancy. If necessary, use immediate-release formulations at lowest effective dose for shortest duration. Extended-release formulations (e.g., 12-hour) are not recommended due to prolonged systemic exposure. Pharmacokinetic changes in pregnancy (increased volume of distribution, reduced plasma concentrations) may necessitate more frequent dosing, but safety data insufficient; avoid.
No specific dose adjustments are established for pregnancy. However, due to increased plasma volume and renal clearance, the duration of action may be shorter. Use the lowest effective dose for the shortest duration, typically 60 mg every 4–6 hours (max 240 mg/day).
Pseudoephedrine is a sympathomimetic amine that causes vasoconstriction; avoid in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Extended-release formulation provides 12-hour symptom relief. Use with caution in patients with diabetes, hyperthyroidism, or prostatic hyperplasia. Monitor for nervousness, dizziness, or insomnia. Not recommended for use with MAOIs or within 14 days of stopping MAOIs.
AFRINOL contains oxymetazoline, an imidazoline sympathomimetic with alpha-adrenergic agonist activity. It causes vasoconstriction in nasal mucosa. Limit use to 3 days to avoid rhinitis medicamentosa. Avoid in patients with narrow-angle glaucoma, severe hypertension, or MAOI use. Onset is within minutes, duration up to 12 hours.
Do not crush or chew the tablet; swallow whole with water.,Take with food or milk if stomach upset occurs.,Avoid taking within 4-5 hours of bedtime to prevent insomnia.,Do not exceed one tablet every 12 hours; maximum 2 tablets in 24 hours.,Discontinue and consult doctor if symptoms persist beyond 7 days or are accompanied by fever.,Avoid using other medications containing pseudoephedrine or other decongestants.,Do not use if you have high blood pressure, heart disease, or are taking MAOIs.
Do not use for more than 3 consecutive days to avoid rebound congestion.,Do not share the bottle with others to prevent infection.,Do not exceed recommended dosage; use only 2-3 sprays per nostril every 10-12 hours as directed.,Avoid using if you have high blood pressure, heart disease, or glaucoma without consulting a doctor.,Consult a doctor if symptoms persist beyond 3 days or if you experience severe side effects like headache, rapid heartbeat, or dizziness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUDAFED 12 HOUR vs AFRINOL, answered by our medical review team.
SUDAFED 12 HOUR is a Decongestant that works by Pseudoephedrine is a sympathomimetic amine that acts as an agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of nasal mucosa and reducing nasal congestion.. AFRINOL is a Decongestant that works by Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUDAFED 12 HOUR and AFRINOL depend on the specific clinical indication. These are both Decongestant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUDAFED 12 HOUR is: 120 mg orally every 12 hours, extended-release tablets. Maximum 240 mg per day.. The standard adult dose of AFRINOL is: Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUDAFED 12 HOUR and AFRINOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUDAFED 12 HOUR is classified as Category C. Category C. First trimester: Possible risk of gastroschisis (limited data). Second and third trimesters: Uterine vasoconstriction, reduced placental perfusion; avoid due to risk of. AFRINOL is classified as Category C. Afrinol (pseudoephedrine) is generally considered low risk during pregnancy. First trimester: Some studies suggest a possible association with gastroschisis, but data are inconsist. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.